Alta Advisers’s Regeneron Pharmaceuticals REGN Stock Holding History

Alta Advisers’s Portfolio REGN Stock Details REGN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q3	$558K	Buy	736 +329	+81%	+$249K	0.08%	145
2026 Q2	$254K	Hold	407	–	–	0.06%	184
2026 Q1	$314K	Hold	407	–	–	0.11%	127
2025 Q4	$314K	Sell	407 -200	-33%	-$136K	0.11%	124
2025 Q3	$341K	Hold	607	–	–	0.1%	159
2025 Q2	$319K	Hold	607	–	–	0.11%	162
2025 Q1	$385K	Buy	607 +250	+70%	+$172K	0.16%	125
2024 Q4	$254K	Buy	357 +57	+19%	+$47.8K	0.16%	122
2024 Q3	$315K	Hold	300	–	–	0.14%	84
2024 Q2	$315K	Hold	300	–	–	0.15%	80
2024 Q1	$289K	Hold	300	–	–	0.14%	88
2023 Q4	$263K	Hold	300	–	–	0.14%	90
2023 Q3	$247K	Hold	300	–	–	0.14%	84
2023 Q2	$216K	Hold	300	–	–	0.12%	100
2023 Q1	$247K	Hold	300	–	–	0.15%	86
2022 Q4	$216K	Hold	300	–	–	0.13%	94
2022 Q3	$207K	Buy	+300	New	+$189K	0.13%	84

Other funds holding REGN

BlackRock New York $6.79T AUM 37.06% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.76T AUM

State Street Boston, Massachusetts $3.44T AUM 36.12% 1-Year Est. Return

Dodge & Cox San Francisco, California $187B AUM 13.73% 1-Year Est. Return

Invesco Atlanta, Georgia $1.27T AUM 50.62% 1-Year Est. Return

Franklin Resources San Mateo, California $474B AUM 32.39% 1-Year Est. Return

JP Morgan Chase New York $1.84T AUM 33.86% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.21T AUM

Geode Capital Management Boston, Massachusetts $1.92T AUM 36.1% 1-Year Est. Return

Nuveen Charlotte, North Carolina $420B AUM 34.97% 1-Year Est. Return

Alta Advisers's REGN Position: Q3 2026 in Review

Alta Advisers increased its Regeneron Pharmaceuticals (REGN) stake by 81% in Q3 2026, buying an estimated $249K and bringing the position to 736 shares worth $558K. The position accounts for 0.08% of the portfolio, ranked #145.

Alta Advisers first reported a position in REGN in Q3 2022 and has held it in 17 quarters since. 1,212 funds tracked by Wall St. Rank hold REGN as of Q3 2026.

Alta Advisers held 736 shares of Regeneron Pharmaceuticals worth $558K as of Q3 2026.
Alta Advisers bought 329 Regeneron Pharmaceuticals shares in Q3 2026, an estimated $249K.
Regeneron Pharmaceuticals made up 0.08% of Alta Advisers's portfolio in Q3 2026, its #145 holding.
Alta Advisers first reported a position in Regeneron Pharmaceuticals in Q3 2022 and has held it in 17 quarters since.
1,212 funds tracked by Wall St. Rank held Regeneron Pharmaceuticals as of Q3 2026.

Based on Alta Advisers's 13F filing for Q3 2026, filed 2 Nov 2026.